32,829 Shares in Progyny, Inc. $PGNY Bought by The Manufacturers Life Insurance Company

Posted by Francis Steltz on Sep 6th, 2026

The Manufacturers Life Insurance Company purchased a new stake in Progyny, Inc. (NASDAQ:PGNY – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 32,829 shares of the company’s stock, valued at approximately $946,000.

Other large investors have also bought and sold shares of the company. Royal Bank of Canada grew its stake in shares of Progyny by 384.8% in the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock worth $291,000 after acquiring an additional 10,340 shares in the last quarter. Amundi boosted its holdings in Progyny by 103.8% during the first quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after purchasing an additional 5,817 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Progyny by 6.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock worth $5,630,000 after purchasing an additional 14,297 shares in the last quarter. Invesco Ltd. grew its position in Progyny by 37.4% in the 2nd quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock worth $8,342,000 after purchasing an additional 103,253 shares in the last quarter. Finally, Walleye Capital LLC increased its stake in Progyny by 6.9% in the 2nd quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock valued at $266,000 after buying an additional 780 shares during the last quarter. 94.93% of the stock is currently owned by institutional investors.

Progyny Stock Down 2.5%

PGNY opened at $25.94 on Friday. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of 28.20, a PEG ratio of 1.79 and a beta of 0.99. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $33.06. The company’s 50-day moving average price is $28.97 and its two-hundred day moving average price is $23.79.

Progyny (NASDAQ:PGNY – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. The company had revenue of $350.51 million during the quarter, compared to analyst estimates of $349.05 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. Progyny’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.19 EPS. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, sell-side analysts anticipate that Progyny, Inc. will post 1.25 earnings per share for the current year.

Progyny announced that its board has approved a stock buyback plan on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 10.3% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PGNY. JPMorgan Chase & Co. boosted their target price on Progyny from $27.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, August 21st. Canaccord Genuity Group set a $35.00 price target on Progyny in a research report on Friday, August 7th. Truist Financial lifted their price target on Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Bank of America boosted their price objective on Progyny from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Finally, KeyCorp upped their price objective on Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $33.91.

Get Our Latest Research Report on Progyny

Progyny Company Profile

(Free Report)

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.